Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 8/20 | 1.00 |
| ▸ | ITGB2 | P05107 | 5/20 | 1.00 |
| ▸ | ITGAM | P11215 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | CASP3 | P42574 | 1/20 | 0.68 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.68 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.68 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | APEX1 | P27695 | 2/20 | 0.61 |
| ▸ | PTGES | O14684 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5145237 | 0.92 | SLC1A3 (1.00) | SLC1A3ITGB2ITGAMMEN1KMT2A | |
| SCHEMBL5145242 | 0.92 | SLC1A3 (1.00) | SLC1A3ITGB2ITGAMMEN1KMT2A | |
| SCHEMBL5147456 | 0.90 | SLC1A3 (0.88) | SLC1A3ITGB2ITGAMMEN1KMT2A | |
| SCHEMBL46577 | 0.90 | SLC1A3 (0.88) | SLC1A3ITGB2ITGAMMEN1KMT2A | |
| SCHEMBL29494140 | 0.88 | SLC1A3 (0.79) | SLC1A3ITGB2ITGAMMEN1KMT2A | |
| SCHEMBL46561 | 0.85 | ITGB2 (1.00) | SLC1A3ITGB2ITGAMMEN1KMT2A | |
| SCHEMBL6392207 | 0.84 | MEN1 (0.87) | SLC1A3ITGB2ITGAMMEN1KMT2A | |
| SCHEMBL6392210 | 0.84 | MEN1 (0.87) | SLC1A3ITGB2ITGAMMEN1KMT2A | |
| SCHEMBL21337634 | 0.84 | SLC1A3 (0.82) | SLC1A3ITGB2ITGAMMEN1KMT2A | |
| SCHEMBL14426579 | 0.83 | LCK (0.86) | SLC1A3ITGB2ITGAMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3243821-B1 | PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 | GB006 INC (US) | 2020-02-26 | — | — | EP | disclosed |
| EP-2838614-B1 | COMPOSITIONS FOR REGULATING INTEGRINS | GB006 INC (US) | 2019-09-11 | — | — | EP | disclosed |
| US-10239871-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239871-B2 | Compounds and methods for regulating integrins | ITGA2, ITGB2, ITGA2B | SLC1A3 4237/4885ITGB2 2/4885ITGAM 9/4885 |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ITGB8, ITGB3, ITGAM | SLC1A3 3928/4885ITGB2 5/4885ITGAM 3/4885 |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | SLC1A3 4237/4885ITGB2 2/4885ITGAM 9/4885 |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | SLC1A3 4237/4885ITGB2 2/4885ITGAM 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.